

Pharmacy Formulary Updates for February 2021

To offer a pharmacy benefit that is clinically appropriate and cost effective, we constantly review how we cover prescription medications. Periodic adjustments are made to meet these goals. The changes below are reflected in our online drug list.

The following is a list of drugs that changed formulary status in February 2021:

Drug Name	Tufts Health Plan Commercial Formularies						
	Massachusetts				Rhode Island		
	Large Group 3-Tier Formulary	Large Group 4-Tier Formulary	Small Group/ Individual 3-Tier (Exchange Formularies)	Small Group/ Individual 4-Tier (Exchange Formularies)	Large Group 3-Tier Formulary	Large Group 4-Tier Formulary	Small Group/ Individual 4-Tier (Exchange Formularies)
Fosfomycin tromethamine	Tier 2						
Samsca® 30 mg	NC						
Vumerity®	Tier 2; SP	Tier 4; SP	Tier 2; SP	Tier 4; SP	Tier 2	Tier 4	Tier 4
rufinamide 40mg/ml suspension	Tier 2; QL						
norethindrone acetate-ethinyl estradiol-Fe	T1; ACA						
Qdolo (tramadol hcl)	NC; QL						
Impeklo™ (clobetasol propionate)	NC						
Mycapssa®	Tier 3; PA	Tier 4; PA	Tier 3; PA	Tier 4; PA	Tier 3; PA	Tier 4; PA	Tier 4; PA
Kesimpta® (ofatumumab)	Tier 2; SP	Tier 4; SP	Tier 2; SP	Tier 4; SP	Tier 2	Tier 4	Tier 4
Reditrex™ (methotrexate)	NC						
Conjupri® (levamlodipine maleate)	NC						
CGM Receiver	Excluded						
CGM Transmitter	Excluded						
CGM Sensor Pack	Excluded						

Key:

MM Managed Mail – must fill at mail order pharmacy

NC Not covered

SP Specialty Pharmacy

ST^{PA} Step Therapy Prior Authorization

PA Prior Authorization
QL Quantity Limitation

MB Medical Benefit
SI Specialty Infusion